Since its identification in 1988,1 endothelin has attracted intensive interdisciplinary research interest because of its unique profile as an endothelium-derived vasoactive factor with a powerful and characteristically long-lasting vasopressor activity. Indeed, in terms of cellular mechanisms of action, endothelin appears to be quite similar to many classic vasoconstrictor substances such as angiotensin II (ECE).4 The production of endothelins is tightly regulated at the level of mRNA transcription. In vascular endothelial cells, ET-1, once synthesized, is secreted via the constitutive pathway of secretion without further regulation at the level of exocytosis. Endothelins are expressed on proper stimulation in various cell types, although vascular endothelial cells appear to be the most abundant source of ET-1 in vivo under healthy conditions, and the endothelial cells produce only ET-1. It seems reasonable to consider that endothelins act primarily as local, paracrine/autocrine hormones, because (1) the "target" cell types that have endothelin receptors can always be found in the vicinity of the "producer" cell types within the same tissue; (2) circulating plasma levels of endothelins are generally much lower than the threshold concentrations for pharmacological activities; and (3) This leads to a variety of cellular actions depending on the target cell types, eg, contraction and proliferation of vascular smooth muscle cells. In contrast, the two receptor subtypes have highly distinct isopeptide selectivities: although the ETA subtype has an affinity rank order of ET-1 .ET-2> >ET-3 (ET-3 often acts only as a partial agonist), the ETB receptor accepts all three isopeptides equally. The molecular subdomains of the receptors that determine this ligand selectivity have also been delineated.7
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The endothelins are a family of 21- This leads to a variety of cellular actions depending on the target cell types, eg, contraction and proliferation of vascular smooth muscle cells. In contrast, the two receptor subtypes have highly distinct isopeptide selectivities: although the ETA subtype has an affinity rank order of ET-1 .ET-2> >ET-3 (ET-3 often acts only as a partial agonist), the ETB receptor accepts all three isopeptides equally. The molecular subdomains of the receptors that determine this ligand selectivity have also been delineated. 7 Because of the way in which these receptor subtypes were initially discovered,8 in the past it was believed that the ETA and ETB receptors have clearly demarcated anatomic and functional territories in vascular tissues: the smooth muscle ETA receptors mediate direct vasoconstrictor actions of endothelins, whereas the endothelial ETB receptors produce vasodilator effects via the endothelin-induced release of nitric oxide. However, this simple model does not hold anymore in view of the accumulating lines of recent evidence in both experimental animals and humans.
The report in this issue of Circulation by Seo and colleagues9 provides the first definitive evidence that both ETA and ETB receptors are involved in the vasoconstrictor action of endothelins in human blood vessels, further emphasizing the complexity of the vascular roles for endothelin receptor subtypes. The consensus in the field has become that the endothelium-dependent relaxation induced by endothelins, if it is at all observed, is always mediated by the ETB receptor, regardless of species and vascular regions; and that relative contributions of the ETA and ETB subtypes to the vasopressor responses vary greatly depending on both species and the vasculature in question. These findings have enormous implications in terms of the discovery and development of a novel modality of therapeutics that make use of endothelin receptor antagonists. Virtually all major players in the pharmaceutical industry are involved in this race of drug discovery. Now they face an interesting situation-thanks to the modern methods of rational molecular design and mass screening with cloned receptors, the discovery of antagonists with a favorite subtype selectivity (ie, ETA selective, ETB selective, or nonselective) itself is not a problem anymore. Indeed, a number of peptidic antagonists, which are extremely useful at least as research tools, have been discovered.21"22 More recently, Clozel and colleagues23 reported the first orally active nonpeptidic antagonist. Rather, a real challenge in the field is to find the right animal models of potential target human disease and to match those models with antagonists having the right receptor subtype selectivity. As the aforementioned findings clearly dictate, there would be no benefit if a wrong model species or a drug with the wrong subtype selectivity were chosen. Also, it will be extremely difficult to predict the effects of a candidate drug in humans, especially in the current dearth of precise pharmacological studies in humans. However, an obvious lesson from these recent studies is that the initial hypothesis is invalid, where the ETA receptors were portrayed as bad guys and the ETB as saints. Research in the field clearly needs to address the pathophysiological roles of both receptor subtypes separately, without negligent a priori assumptions.
Thus, the situation is complicated due to the fact that the ETB subtype can act as either vasoconstrictor or vasodilator receptor depending on the vasculature and species. One must be extremely careful in designing and interpreting a study that involves ligands that are active on ETB receptors. The current lack of a good, published ETB-selective antagonist makes it even more problematic. In this regard, a recent study by Warner and colleagues24 suggests the possible existence of subsubtypes of ETB receptors; they postulated a dilator (or endothelial) ETB receptor that is sensitive to the hexapeptide ETA/ETB nonselective antagonist PD 142893 and a constrictor ETB subsubtype that is resistant to this class of compound. However, these organ-bath findings have to be substantiated by radioligand binding assays and molecular cloning studies before any definitive conclusion can be derived.
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